Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%.
hello world
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
